АБАТАЦЕПТ — НОВЫЕ ВОЗМОЖНОСТИ ТЕРАПИИ ЮВЕНИЛЬНОГО ИДИОПАТИЧЕСКОГО АРТРИТА
Аннотация
Ключевые слова: дети, ревматоидный артрит, абатацепт, лечение.
(Вопросы современной педиатрии. 2009;8(4):84-89)
Об авторах
Е.И. АлексееваРоссия
Р.В. Денисова
Россия
С.И. Валиева
Россия
Т.М. Бзарова
Россия
Список литературы
1. Oliveira S., Ravelli A., Pistorio A. et al. Proxy-reported healthrelated quality of life of patients with juvenile idiopathic arthritis: the Pediatric Rheumatology International Trials Organization multinational quality of life cohort study. Arthritis Rheum. 2007; 57: 35–43.
2. Ravelli A., Martini A. Juvenile idiopathic arthritis. Lancet. 2007; 369: 767–778.
3. Ruperto N., Levinson J. E., Ravelli A. et al. Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. I. Outcome status. J. Rheumatol. 1997; 24: 945–951.
4. Hashkes P. J., Laxer R. M. Medical treatment of juvenile idiopathic arthritis. JAMA. 2005; 294 (13): 1671–1684.
5. Minden K., Kiessling U., Listing J. et al. Prognosis of patients with juvenile chronic arthritis and juvenile spondyloarthropathy. J. Rheumatol. 2000; 27 (9): 2256–2263.
6. Wilkinson N., Jackson G., Gardner–Medwin J. Biologic therapies for juvenile arthritis. Arch. Dis. Child. 2003; 88 (3): 186–191.
7. Smolen J. S., Steiner G. Theraueutic strategies for rheumatoid arthritis. Nat. Rev. Drug Discov. 2003; 2: 473–488.
8. Pettit A. R., Thomas R. Dendritic cells: the driving force behind autoimmunity in rheumatoid arthritis. Immunol. Cell Biol. 1999; 7: 420–427.
9. Bretscher P. A. A two-step, two-signal model for the primary activation of precursor helper T cells. Proc. Natl. Acad. Sci. USA. 1999; 96: 85–90.
10. Choy E. H., Panayi G. S. Cytokine pathways and joint inflammation in rheumatoid arthritis. New Engl. J. Med. 2001; 344: 907–916.
11. Yamada A., Salama A. D., Sayegh M. H. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J. Am. Soc. Nephrol. 2002; 13: 559–575.
12. Chambers C. A., Allison J. P. CTLA-4 — the costimulatory molecule that doesn't: regulation of T-cell responses by inhibition. Cold Spring Harb. Symp. Quant. Biol. 1999; 64: 303–312.
13. Davies P., Zhou L., Abraham R. Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. J. Rheumatol. 2007; 34: 280–289.
14. Linsley P. S., Brady W., Urnes M. et al. CTLA–4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 1991; 174 (3): 561–569.
15. Kremer J. M., Dougados M., Emery P. et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve month results of a phase IIb, double blind, randomized, placebo controlled trial. Arthritis Rheum. 2005; 52: 2263–2271.
16. Webb L. M., Walmsley M. J., Feldmann M. Prevention and amelioration of collagen–induced arthritis by blockade of the CD28 co–stimulatory pathway: requirement for both B7–1 and B7–2. Eur. J. Immunol. 1996; 26: 2320–2328.
17. Moreland L. W., Alten R., Bosch F. et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose finding, doubleblind, placebo-controlled clinical trial evaluating CTLA–4Ig and LEA29Y eighty five days after the first infusion. Arthritis Rheum. 2002; 46: 1470–1479.
18. Kremer J. M., Westhovens R., Leon M. et al. Treatment of rheumatoid arthritis by selective inhibition of T–cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 2003; 349: 1907–1915.
19. Kremer J. M., Dougados M., Emery P. et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve month results of a phase IIb, double blind, randomized, placebo controlled trial. Arthritis Rheum. 2005; 52: 2263–2271.
20. Kremer J. M., Genant H. K., Moreland L. W. et al. Effects of abatacept in patients with methotrexate resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 2006; 144: 865–876.
21. Genovese M. C., Becker J. C., Schiff M. et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 2005; 353: 1114–1123.
22. Schiff M. H., Pritchard C., Huffstutter J. E. et al. The 6 month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-TNF therapy or were directly switched to abatacept: the ARRIVE trial. Ann. Rheum. Dis. 2009. URL: http: // ard.bmj.com/cgi/ rapidpdf/ard.2008.099218v1.
23. Schiff M., Keiserman M., Codding C. et al. Efficacy and safety of abatacept or infliximab VS placebo in ATTEST: a phase III, multicentre, randomised, double blind, placebo controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann. Rheum. Dis. 2008; 67: 1096–1103.
24. Kremer J. M., Genant H. K., Moreland L. W. et al. Results of a two year follow up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 2008; 58: 953–963.
25. Genant H. K., Peterfy C. G., Westhovens R. et al. Abatacept inhibits structural damage progression in rheumatoid arthritis: results from the long–term extension of the AIM trial. Ann. Rheum. Dis. 2008; 67: 1084–1089.
26. Weinblatt M., Combe B., Covucci A. et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease–modifying antirheumatic drugs: a one–year randomized, placebo–controlled study. Arthritis Rheum. 2006; 54: 2807–2816.
27. Weinblatt M., Schiff M., Goldman A. et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann. Rheum. Dis. 2007; 66: 228–234.
28. Westhovens R. Robles M., Ximenes A. D. et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann. Rheum. Dis. 2009. URL: http: // ard.bmj.com/cgi/rapidpdf/ard.2008.101121v1.
29. Emery P., Durez P., Dougados M. et al. Efficacy of abatacept in delaying the development of rheumatoid arthritis (RA) in adult patients with undifferentiated inflammatory arthritis at high risk of developing RA [OP–0130]. Ann. Rheum. Dis. 2008; 67 (Suppl. II): 89.
30. Westhovens R., Kremer J., Moreland L. et al. Durable impact on disease activity and consistent safety through 5 years in abatacepttreated RA patients background methotrexate [FRI0171]. Ann. Rheum. Dis. 2008; 67 (Suppl. II): 341.
31. Weisman M. H., Durez P., Hallegua D. et al. Reduction of inflammatory biomarker response by abatacept in the treatment of rheumatoid arthritis. J. Rheumatol. 2006; 33: 2162–2166.
32. Sibilia J., Westhovens R. Safety of T–cell co–stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin. Exp. Eheumatol. 2007; 25 (Suppl. 46): 46–56.
33. Bristol–Myers Squibb: Summary of product characteristic. 2007. URL: http:// www.emea.europa.eu/humandocs/PDFs/EPAR/orencia?H–701–PI–en.pdf.
34. Bigbee C. L., Gonchoroff D. G., Vratsanos G. et al. Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice. Arthritis Rheum. 2007; 56: 2557–2565.
35. Ruperto N., Lovell D. J., Quartier P. et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008; 372 (9636): 383–391.
36. Angeleshan S., Flynn T., Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis — a case report. J. Rheumatol. 2008; 35 (9): 1897–1898.
Рецензия
Для цитирования:
Алексеева Е., Денисова Р., Валиева С., Бзарова Т. АБАТАЦЕПТ — НОВЫЕ ВОЗМОЖНОСТИ ТЕРАПИИ ЮВЕНИЛЬНОГО ИДИОПАТИЧЕСКОГО АРТРИТА. Вопросы современной педиатрии. 2009;8(4):84-89.
For citation:
Alexeeva E., Denisova R., Valieva S., Bzarova T. ABATACEPT — NEW OPPORTUNITIES IN TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS. Current Pediatrics. 2009;8(4):84-89.
Послать статью по эл. почте 
